Recent experimental data indicate a pathogenic role of complement activation in congestive heart failure (CHF). The aim of this study was to evaluate contact and complement systems activation in patients hospitalized for an acute episode of CHF. Forty-two of 80 consecutive patients admitted at our hospital with confirmed diagnosis of acute CHF were enrolled. They underwent blood sampling within 24 h from admission (T0) and at clinical stability (T1). Patients were stratified for ejection fraction (EF) based on echocardiographic test. We measured plasma levels of C3, C4, sC5b-9 and cleaved high molecular weight kininogen (contact activation marker). At T1, C3 levels increased significantly compared to T0 (97 6 2 versus 104 6 3% of total pooled plasma, P < 0Á01). Classifying patients according to EF, only patients with preserved EF presented a significant increase of C3 from T0 to T1 (99 6 3 versus 108 6 4%, P 5 0Á03). When the sample was stratified according to clinical outcome, C3 (98 6 3 versus 104 6 4%, P 5 0Á03) and sC5b-9 levels (204 6 10 versus 230 6 11 ng/ml, P 5 0Á03) were increased in patients who had positive outcome after hospitalization. CHF patients with preserved EF and positive outcome after hospitalization showed higher levels of sC5b-9 in the T1 period compared with T0 (211 6 14 versus 243 6 14 ng/ml, P 5 0Á04). Our results suggest that the complement system reacts differently if CHF occurs with preserved or reduced EF. This finding is interesting if we consider the difference in epidemiology, pathogenesis and possible therapeutic approaches of these two clinical entities.
Introduction
Congestive heart failure (CHF) is a chronic complex clinical syndrome characterized by signs and symptoms that may result from both peripheral hypoperfusion and systemic and/or pulmonary congestion. Despite progress in the therapeutic field that has led to improved outcomes, the prognosis of CHF is still poor and the clinical history is characterized by frequent hospitalizations and significant deterioration of quality of life.
Currently, heart failure (HF) is classified according to the type of ventricular dysfunction that affects contractility and/or relaxation of the left ventricle (LV) [1] . Briefly, patients with HF and systolic dysfunction (LF ejection fraction, LVEF < 40%) due to cardiac eccentric remodelling are classified into HF with reduced ejection fraction (HFrEF). Patients with HF, preserved systolic function (LVEF > 50%), but diastolic dysfunction due to cardiomyocyte hypertrophy, interstitial fibrosis and capillary rarefaction, that lead to concentric cardiac remodelling, are classified as HF with preserved ejection fraction (HFpEF) [1] .
It is well known that neurohumoral dysfunction, which includes renin-angiotensin-aldosterone system (RAAS) activity and autonomic nervous system derangement, plays a key role in the pathophysiology and clinical evolution of HFrEF. Increased sympathetic activity and progressive loss of rhythmical sympathetic oscillation [2, 3] are associated with poor prognosis [4] . On the contrary, pathophysiology of HFpEF is multi-factorial and related not only to diastolic dysfunction but also to structural changes, diffuse fibrosis and arterial stiffness. In addition, HFpEF has a high prevalence of comorbidities (hypertension, diabetes, atrial fibrillation), and several studies demonstrate the participation of oxidative stress, endothelial dysfunction and pathophysiological inflammation [5] [6] [7] . The role of the immunoinflammatory system is highlighted further by evidence that endothelins, tumour necrosis factor (TNF)-a and reactive oxygen species influence the course and prognosis of CHF [7] that, today, should be seen as a systemic disease and not just as a disease of the cardiac muscle.
The complement system is part of the innate immune system and is an important participant in the immuneinflammatory reaction. It activates through pattern recognition mechanisms and proceeds with a proteolytic cascade that ends in cell lysis and damage. During the activation process, it releases bioactive peptides that induce opsonization, chemotaxis of immune cells, inflammatory signalling, cell adhesion and phagocytosis [8] . Biomaterials as well as damaged endothelial cells, are potent complement activators and activate the contact system that intervenes in the inflammatory process releasing vasoactive kinins at the same time [9] [10] [11] . Complement activation occurs in atrial fibrillation and the plasma levels of complement components may be used as prognostic indicators [12] . Wei et al. [13] demonstrated that chronic myocardial stretch of a pure volume overload causes up-regulation of the kallikrein-kinin system, with an increase in interstitial fluid bradykinin that can mediate mast cell infiltration and extracellular matrix loss.
The complement and contact kallikrein-kinin systems may activate under identical circumstances and trigger reciprocal amplification loops [14, 15] . Such a condition is demonstrated clearly in hereditary angioedema, where C1 inhibitor deficiency causes episodic increases in vascular permeability mediated by bradykinin [16] . Nevertheless, no study has examined kinin-forming and complement systems in patients suffering acute CHF and the relationship of these parameters to short-term outcome.
The aim of this study was to evaluate contact and complement systems activation in patients hospitalized for an acute episode of CHF and to examine the relationship between the degree of activation and mild-term clinical outcome. To answer these questions, we measured the relative amount of the cleaved form of high molecular weight kininogen (HK), indirect evidence of bradykinin generation and complement system activation by means of C3, C4 and sC5b-9 levels in patients with CHF during the acute phase.
Materials and methods

Study protocol
The study protocol was drawn up in collaboration with the Johnson Space Center, NASA in Houston (TX, USA) and was approved by the Institutional Review Board of our hospital (Luigi Sacco Hospital, University of Milan, Italy). All the patients enrolled signed an informed consent.
From March 2013 to June 2014, we screened 80 patients with a diagnosis of acute CHF within 24 h from admission in the operative units of three medicine divisions of our hospital. The diagnosis was based on clinical evaluation, radiological assessment (chest X-ray), lung ultrasound and blood tests, according to international guidelines (European Society of Cardiology Guidelines). Exclusion criteria included: severe cognitive impairment, previous history of transplantation, pharmacological immunosuppression, HIV/AIDS, surgery in the last month and ongoing infection.
Forty-two of 80 patients fulfilled the inclusion criteria and were enrolled into the study. They underwent blood sampling within 24 h of admission (T0) and from clinical stability (T1). Criteria for clinical stability were: improvement of the respiratory function and arterial blood gas exchange, reduced peripheral oedema at levels at least comparable to those present before admission and improvement in the imaging studies of the lungs (such as chest Xray or pulmonary ultrasound). Patients were stratified for ejection fraction (EF) based on echocardiographic test performed during hospitalization or within 15 days before admission, in accordance with standard guidelines [17] . We performed a telephone follow-up 2 months after discharge to collect the following data: death from all causes, rehospitalization and relapse of decompensation. In the presence of one of these events, the short-term outcome was considered negative; in the absence of all three events, the short-term outcome was considered positive.
Blood sampling
During the T0 and T1 periods, blood samples were obtained by clean venipuncture and minimal stasis. Plasma for the measurement of C3 and C4 was collected in sodium citrate and for sC5b-9 in ethylenediamine tetraacetic acid (EDTA) with a final concentration of 20 mM, to prevent in-vitro classical pathway complement activation [18] . To prevent contact system activation in the measurement of cleaved HK, blood was drawn directly into vacutainer tubes containing 100 mM benzamidine, 400 lg/ml hexadimethrine bromide, 2 mg/mL soybean trypsin inhibitor, 263 lM leupeptin and 20 mM aminoethylbenzene-sulphonyl fluoride dissolved in acid/citrate/dextrose (100 mM trisodium citrate, 67 mM citric acid and 2% dextrose, pH 4Á5). Nine parts of blood were mixed with one part of the anti-coagulant/inhibitor cocktail mixture [19] . Blood samples were centrifuged within 1 h at 2000 g and 208C for 20 min. The plasma was removed, divided into aliquots and stored at 2808C until tested.
Laboratory methods
Complement system. Plasma levels of sC5b-9 were measured with an enzyme-linked immunosorbent assay (ELISA) kit (A029; Quidel, San Diego, CA, USA), according to the manufacturer's instructions. C3 and C4 antigen levels were evaluated using radial immunodiffusion (RID) (NOR-Partigen; Siemens Healthcare Diagnostics, Munich, Germany).
Contact system. The cleavage of HK was assessed by means of sodium dodecyl sulphate-polyacrylamide gel electrophoresis (SDS-PAGE) and immunoblotting analysis [20] . Samples were loaded onto a 9% SDS-polyacrylamide gel. After electrophoretic separation, proteins were transferred from the gel to a polyvinylidene difluoride membrane using the Bio-rad Trans-Blot V R Turbo TM Transfer System (Bio-Rad Laboratories, Hercules, CA, USA). HK was identified using goat polyclonal anti-HK light chain (Nordic, Tilburg, the Netherlands) and visualized using a biotinylated rabbit anti-goat antibody (Sigma Aldrich, St Louis, MO, USA). The apparent molecular masses of the proteins were estimated by comparing them with the highmolecular-weight protein markers (Bio-Rad Laboratories). Using this method, native HK appears as a single band with an M r of 130 000 but, upon maximal cleavage, it is replaced progressively by two bands with M r values of 107 000 and 98 000. The density of the bands was measured using a Bio-Rad GS800 densitometer. Kaolin-incubated plasma was run on each electrophoresis as a control sample. The amount of cleaved HK (with M r bands of 107 000 and 98 000) was expressed as a percentage of total HK (the sum of the three bands) [21] .
Statistics
Descriptive statistics were reported at baseline, with continuous data expressed as means 6 standard error of the mean (s.e.m.) for normally distributed data and categorical data expressed as counts; v 2 was used to assess categorical data differences. For each variable, the Lèvene and Shapiro-Wilk tests were used to assess the distribution of homogeneity and normality, respectively. The comparison between T0 and T1 was performed using a paired t-test, while an unpaired t-test was used to check differences between preserved and impaired EF patients. However, Wilcoxon or Mann-Whitney tests were used when appropriate. A P-value of less than 0Á05 was considered to indicate statistical significance. The analysis was performed with the use of SigmaPlot 12Á5 software (San Jose, CA, USA).
Results
The demographic and clinical characteristics, therapeutic and comorbidities are represented in Table 1 . Ten (24%) patients with CHF had pacemaker/implantable cardioverter defibrillator and the mean distance between T0 and T1 was 10 6 1 days (Table 1) . Twenty-seven patients (64%) were treated with diuretics, 21 (50%) with beta-blockers, 15 (36%) with angiotensin-converting enzyme inhibitors/ angiotensin II receptor blockers (ACEI/ARB), five (12%) with aldosterone antagonists and 10 patients (24%) did not take usual therapy for HF ( Table 1 ). The cardiovascular risk factors most represented in this population are hypertension (30 patients, 71%), followed by diabetes mellitus (21 patients; 50%) and ischaemic heart disease (23 patients; 55%).
According to echocardiographic test, 17 patients had HFrEF (78 6 3 years with 59% males) and 25 patients an HFpEF group (80 6 2 years with 40% males). Age, gender, body mass index (BMI), atrial fibrillation, pacemacker/ implantable cardioverter defibrillator, therapeutic and comorbidity characteristics were similar between groups in the T0 period (Table 1) .
Laboratory data of the sample in admission period (T0) and after clinical stability (T1) are summarized in Table 2 . The leucocyte levels in CHF patients were significantly lower (8135 6 414 versus 6834 6 326/mm 3 , P 5 0Á02) at clinical stability compared to admission (Table 2) . Similar significant differences in leucocyte levels at T1 versus T0 periods were found when analysis was performed in the subgroups of patients with HFrEF (7886 6 845 versus , P < 0Á01). In addition, creatinine levels were significantly higher at clinical stability compared to the admission period in only the HFpEF group (1Á14 6 0Á13 versus 1Á32 6 0Á14 mg/dl, P 5 0Á02). However, no changes in haemoglobin and CRP levels were observed in either group (Table 2) .
After clinical stability, C3 levels increased significantly compared to the admission period (97 6 2 versus 104 6 3% of total pooled plasma, P < 0Á01; Fig. 1 ). Interestingly, when we analysed patients according to EF, we found that only the HFpEF group presented a significant increase of C3 from T0 to T1 (99 6 3 versus 108 6 4% of total pooled plasma, P 5 0Á03; Fig. 1a) . No significant changes in C4, sC5b-9 and cleaved HK levels were found in the general sample (CHF), as well as in the HFrEF and HFpEF groups between T0 and T1 (Fig.1b-d,  respectively) .
When the study population was stratified according to clinical outcome in patients with HF during the acute phase, we observed that C3 (98 6 3 versus 104 6 4% of total pooled plasma, P 5 0Á03; Fig. 2a ) and sC5b-9 levels (204 6 10 versus 230 6 11 ng/ml, P 5 0Á03; Fig. 2c) were increased in CHF patients who had a positive outcome after hospitalization. Interestingly, HFpEF patients with positive outcome after hospitalization showed a higher level of sC5b-9 in the T1 period when compared with the T0 period (211 6 14 versus 243 6 14 ng/ml, P 5 0Á04; Fig.  2c ). Moreover, no significant changes were found in C4 (Fig. 2b) and cleaved HK levels (Fig.2d ) in general sample (CHF) as well as in the HFrEF and HFpEF groups, regardless of clinical outcomes during the study. 1Á19 6 0Á08 1Á30 6 0Á09 1Á26 6 0Á09 1Á27 6 0Á10 1Á14 6 0Á13 1Á32 6 0Á14* Means 6 standard error of the mean. CHF 5 congestive heart failure; CRP 5 C-reactive protein; HFrEF 5 heart failure with reduced ejection fraction; HFpEF 5heart failure with preserved ejection fraction; T0 5 during 24 h from admission of patient; T1 5 after clinical stability of patient. *Difference versus the T0 period (same group), P < 0Á05. Fig. 1 . Level of C3 (a), C4 (b), sC5b-9 (c) and cleaved high molecular weight kininogen (HK) (d) in the whole sample of patients with congestive heart failure (CHF), as well as in the heart failure with reduced ejection fraction (HFrEF) and with preserved ejection fraction (HFpEF) groups during admission (T0 5 white bars) and after the clinical stability (T1 5 grey bars) periods. *Difference versus the T0 period in the same group, P < 0Á05.
Discussion
The findings of previous studies regarding the role of the complement system in patients with heart failure are not conclusive. The present study provides three original findings: (i) C3 increases significantly from T0 to T1 in the entire CHF population; (ii) in patients stratified according to EF, only those with HFpEF show this dynamic; and (iii) patients with positive outcome at 2 months have a significant increase in sC5b-9 during the time elapsing for reversal of the acute symptoms of CHF (T0-T1 values), and this response to treatment is observed only in patients with HFpEF. Hence, two parameters appear to be related to the type of CHF, i.e. with normal or reduced EF. The epidemiology and the pathogenesis of these different forms of heart failure are distinct, involving different mechanisms leading to endothelial dysfunction and cardiac remodelling [22] . In other studies, plasma C3a and sC5b-9 correlated with a more advanced disease and a greater risk of adverse events [23, 24] . Frey et al. [25] found that the levels of C3 had prognostic value, being correlated negatively with cardiac remodelling. C3 is an acute-phase reactant protein and our results reinforce the concept that CHF may have different degrees/types of inflammatory reaction when it is related to diastolic or systolic dysfunction. The fact that CRP does not move consensually with C3 can be explained by the possibility that acute reactant proteins may have different patterns based on the inflammatory stimulus. Well-known examples are bacterial and viral inflammation that elicit different cytokine patterns resulting in C-reactive protein (CRP) and ferritin responses, respectively [26] .
Our third finding is an apparent prognostic value of T0 to T1 changes in the levels of sC5b-9, whose increase correlates with favourable short-term outcome, but the increase is significant only in patients with HFpEF. Whether complement activation is protective or harmful to tissues has been investigated in animal models of ischaemic heart disease. There is dual evidence showing that complement activation increases the size of the infarcted area, but at the same time C5b-9 contribute to the removal of non-viable cells and promote healing of the ischaemic area [27] . No final answer has been given to the dilemma of whether inflammation is friend or foe, and the appropriate extent of antiinflammatory intervention, particularly in the acute phases, remains controversial. The present availability of potent and specific anti-inflammatory agents show the necessity of providing conclusive evidence on the strategy to be followed.
Cleaved HK increases upon activation of the contact system and releases bradykinin, which mediates vasodilation and vascular permeability [28] . It could have a positive effect in CHF other than as vasodilator, improving endothelial function, acting favourably on cardiac remodelling and partially antagonizing the effects of the renin-angiotensin system [29] . Accordingly, subjects genetically deficient in plasma prekallikrein, the main bradykinin-releasing enzyme, appear to have increased risk of hypertension and related complications [30] . Our data show that contact activation is slightly higher in CHF patients with HFpEF, but not reaching statistical significance. In patients with CHF not divided according to EF, Cugno et al. [31] failed to demonstrate increased plasma bradykinin concentrations. This, and a subsequent study from the same group, demonstrates that advanced CHF is characterized by a complex inflammatory reaction that involves the coagulation system, a severe endothelial dysfunction and an increase in proinflammatory cytokines [32] . The different levels of cleaved HK in patients with preserved and reduced EF could indicate that the systemic inflammatory state accompanying the acute phases of CHF may change according to the form of heart failure.
Starting from the hypothesis that acute CHF, being a highly stressful systemic event, could elicit cell-mediated immune response and inflammatory activity, we evaluated complement and contact systems for the first time during an episode of acute heart failure. Our results suggest that these two inflammatory systems react differently based on the fact that CHF occurs with normal or reduced EF. This finding is particularly interesting if we consider the difference in epidemiology, pathogenesis and possible therapeutic approaches of these two clinical entities.
Limitations
The present study has some important limitations. First, the number of patients is still small, and increasing the number of patients will allow more conclusive results to be drawn. Secondly, being a pilot study, we did not analyse complete inflammatory pathways; for instance, through the measure of plasmatic cytokines. Finally, a longer follow-up period would have added important additional information concerning the relationship between contact system activation and long-term follow-up.
